What Are Postbiotics?
Postbiotics are substances produced by microorganisms or extracted from dead microbes, including metabolites (short-chain fatty acids, bacteriocins, vitamins), structural components (peptidoglycans, lipopolysaccharides), and cell-free supernatants. The ISAPP (International Scientific Association for Probiotics and Prebiotics) 2021 consensus defines postbiotics as "a preparation of inanimate microbial cells and/or their components that confers a health benefit on the host."
Examples and Mechanisms
Heat-killed bacteria retain immunomodulatory properties: dead Lactobacillus triggers TLR signaling, activating dendritic cells without infection risk. Cell-free supernatants contain metabolites and secreted compounds; Lacticaseibacillus rhamnosus GG supernatant reduces inflammation markers. Purified postbiotic components (butyrate, bacteriocins, exopolysaccharides) directly exert health benefits: butyrate feeds colonocytes, bacteriocins inhibit pathogens, polysaccharides stimulate mucus secretion.
Advantages Over Live Probiotics
Postbiotics avoid living bacteria's drawbacks: no viability concerns (no refrigeration needed), reduced contamination risk, no translocation to bloodstream in immunocompromised patients, shorter shelf life (~2 years vs. months for probiotics). Heat-killed Lactobacillus plantarum reduces allergic airway inflammation without live bacteremia risk. This makes postbiotics ideal for immunocompromised populations (premature infants, transplant recipients, HIV-positive patients).
Clinical Evidence
Lactobacillus delbrueckii subsp. lactis LB fermented milk (heat-treated) reduces rotavirus diarrhea in children by 40% (compared to placebo). Lacticaseibacillus rhamnosus GG supernatant improves atopic eczema. However, evidence is limited compared to live probiotics; many postbiotics lack clinical trial data. Regulatory pathways treat postbiotics as foods or supplements (varied requirements globally), slowing development.
Regulatory and Practical Landscape
Postbiotics fall between foods and drugs: the EU treats them as foods, the US as dietary supplements or foods, Canada differently again. Standardization is lacking; postbiotic potency varies by manufacturing. Quality assurance (verified metabolite content, manufacturing controls) is essential but inconsistent. Until regulatory clarity improves, clinicians should evaluate postbiotics with skepticism: evidence strength varies widely, and marketing often outpaces science.